Results 81 to 90 of about 7,662 (208)
Атеротромбоз, 2018 Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2].
D. A. Sychev +8 more
doaj +1 more source
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. [PDF]
, 2015 Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and ...
Albaladejo, Pierre +4 more
core +3 more sources
Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1303-1312, May 2025.OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may change in end‐stage renal disease (ESRD) patients with large inter‐individual variabilities (IIVs), leading to altered substrate drug exposure and ultimately elevated safety risk.
Weijie Kong +15 more
wiley +1 more source
Brain and Behavior, Volume 15, Issue 3, March 2025.This manuscript presents two well‐characterized cases of CVT linked to N2O misuse, managed at a French reference center for rare cerebrovascular diseases. To contextualize our findings, we also provide a narrative review of the existing literature, identifying 10 additional cases of CVT associated with N2O use.
Diana Doukhi +8 more
wiley +1 more source
Iraqi Journal of Pharmaceutical Sciences, 2019 The purpose of our study was to develop Dabigatran Etexilate loaded nanostructured lipid carriers (DE-NLCs) using Glyceryl monostearate and Oleic acid as lipid matrix, and to estimate the potential of the developed delivery system to improve oral ...
haithem N Abed, Ahmed A. Hussein
doaj +1 more source
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. [PDF]
, 2015 Patients at thromboembolic risk with non-valvular atrial fibrillation (AF) can now be managed either with a vitamin K antagonist (VKA) or with a fixed dose of a non-VKA oral anticoagulant (NOAC), while patients with valvular AF have been restricted to ...
De Caterina, R, John Camm, A
core +1 more source
Drug Design, Development and Therapy, 2015 Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of ...
Preusch MR +8 more
doaj
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study [PDF]
, 2013 OBJECTIVE: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. DESIGN: Pharmacoepidemiological cohort study.
Charlot, M. +12 more
core +1 more source
British Journal of Clinical Pharmacology, 2010 Eline A, Dubois, Adam F, Cohen
openaire +2 more sources
Acute Myocardial Infarction after Switching from Warfarin to Dabigatran
Oman Medical Journal, 2015 Dabigatran etexilate is a recently approved direct thrombin inhibitor (DTI), which is superior to warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).
Wael Abuzeid, Hatim Al-Lawati, Neil Fam
doaj +1 more source